Inflammation et Plasticité Cancéreuse - Publications
- Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma. Biswas D, Liu Y-H, Herrero J, Wu Y, Moore DA, Karasaki T, … , de Carné Trécesson S, et al. Nature Cancer 6, 86–101 (2025)
- Combining RAS (ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade. Anastasiou P, Moore C, Rana S, Tomaschko M, de Castro A, … , de Carné Trécesson S, et al. Nature Communications 15, 8146 (2024)
- CRISPR–Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer. Boumelha J, de Castro A, Bah N, Cha H, de Carné Trécesson S, Rana S, et al. Cancer Research 84 (14): 2231–2246 (2024)
- The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. Caswell DR, Gui P, Mayekar MK, Law EK, ... , de Carné Trécesson S, et al. Nature Genetics 56(1), 60-73 (2024)
- Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Ng KW, Boumelha J, Enfield KSS, Almagro J, Cha H, ... , de Carné Trécesson S, et al. Nature 616(7957), 563-573 (2023)
- Genomic-transcriptomic evolution in lung cancer and metastasis. Martinez-Ruiz C, Black JRM, Puttick C, Hill MS, ... , de Carné Trécesson S, et al. Nature 616(7957), 543-552 (2023)
- RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma. East P, Kelly GP, Biswas D, Marani M, Hancock DC, Creasy T, ... & de Carné Trécesson S*. Nature Communications 13(1), 5632 (2022) *corresponding authors
- An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations. Boumelha J*, de Carné Trécesson S*, Law EK*, Romero-Clavijo P, et al. Cancer Research 82(19), 3435-3448 (2022) *co-first authors
- Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Coelho MA, de Carné Trécesson S, Rana S, Zecchin D, Moore C, et al. Immunity 47(6), 1083-1099 (2017)
- BCL-XL directly modulates RAS signalling to favour cancer cell stemness. de Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, et al. Nature Communications 8(1), 1123 (2017)
